Incannex Commences Phase 2 Dosing and Extends IP Protection
Incannex Healthcare provides a corporate update, reporting patient dosing in the DReAMzz Phase 2 study of IHL-42X for obstructive sleep apnea and the grant of a U.S. composition patent expiring in 2040, supported by approximately $70 million in cash.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day